TerminatedNCT01568229

20110165: Study to Evaluate the Effect of AMG 747 on Schizophrenia Negative Symptoms (Study 165)

Medication studyAges 18–60Multiple countries

The study in practice

Understand this study

Listed age limits: 18 years to 60 years.

Listed locations: Little Rock and 43 more locationsSee all locations and recruitment
Study phase: Phase 2

A point to clarify

This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?

Study clarity

Study start dateMay 2012

Recruitment status: Terminated
Enrollment listed in the registry: 111
Sponsor: Amgen
Sponsor type: Unknown or unclear
Study type: Drug
Intervention type: Medication / drug
Study phase: Phase 2
Locations: United States, France, United Kingdom, ...
Age range: From 18 Years to 60 Years
Official registry ID: NCT01568229
Official title: Show the full official title
A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effect of Add-on AMG 747 on Schizophrenia Negative Symptoms

Terminated

Little Rock, United States · Springdale, United States · Long Beach, United States

38 more locations

A listed location does not confirm current availability.

FAQ

Who is behind this study?

The study sponsor is Amgen.

Does this study involve medication?

Yes. The study involves medication, including AMG 747 and Placebo.

Who can participate?

Listed age limits: 18 years to 60 years.

Is this study still recruiting?

The registry lists this study as terminated.